BioPharma Dive
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
BioPharma Dive
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
BioPharma Dive
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.